Cancer

August 26, 2021

Obese children, young adults at higher risk for thyroid cancer

Children and young adults who are obese are at greater risk for malignant thyroid nodules, according to new study from Monroe Carell Jr. Children’s Hospital at Vanderbilt.

By Christina Echegaray
August 23, 2021

‘DNA’ podcast Season 2 explores COVID, science and trust in communities

By Holly Fletcher
August 19, 2021

Park named to new role as deputy director of Vanderbilt-Ingram Cancer Center

Ben Ho Park, MD, PhD, Cornelius Abernathy Professor of Medicine, has been named deputy director of Vanderbilt-Ingram Cancer Center (VICC).

By Tom Wilemon
Rocker George Thorogood, right, shown here with Ronald Alvarez, MD, MBA, recently made a donation to Vanderbilt-Ingram Cancer Center (VICC) from the Marla Thorogood Memorial Fund for Ovarian Cancer Research and plans to do more in memory of his wife, Marla, who he lost to ovarian cancer in 2019. In September, a limited-edition T-shirt featuring the Destroyers logo will be available for purchase online and at shows during the “Good to Be Bad Tour.” Sales will benefit cancer research at VICC.
August 19, 2021

Supporting ovarian cancer research

Rocker George Thorogood recently made a donation to Vanderbilt-Ingram Cancer Center (VICC) from the Marla Thorogood Memorial Fund for Ovarian Cancer Research.

By VUMC News and Communications
August 19, 2021

Jackson elected fellow of American Association of Nurse Practitioners

Heather Jackson, PhD, APRN, administrative director of Advanced Practice for Vanderbilt-Ingram Cancer Center, has been elected a fellow of the American Association of Nurse Practitioners.

By Matt Batcheldor
August 12, 2021

Study identifies biomarker for breast cancer response to immunotherapy

A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

By Tom Wilemon
August 5, 2021

Facebook campaign quickly nets clinical trial participants

The cost and effectiveness of social media as a participant recruitment tool for clinical research is still being evaluated. To better understand its utility, researchers at Vanderbilt University Medical Center used Facebook to mount a short, monthlong pilot campaign in and around Houston attempting to recruit participants for an ongoing smoking cessation study being conducted in that city.
By Paul Govern
August 5, 2021

Clinical trial to test immunotherapy for rectal cancer

A new clinical trial seeks to determine whether immunotherapy in combination with short-course radiation followed by surgical resection could be a curative treatment for locally advanced rectal cancer.
By Tom Wilemon
August 4, 2021

Study finds genetic factor undermines H. pylori treatment

Helicobacter pylori, a stomach-dwelling bacterium, is a strong risk factor for gastric cancer, peptic ulcers and other debilitating gastrointestinal disorders. Yet efforts to eradicate it using a combination of antibiotics and proton pump inhibitors (PPIs), which suppress gastric acid production, often fail.
By Bill Snyder
July 27, 2021

Prediction models for breast cancer

Vanderbilt researchers developed new prognostic models for breast cancer outcomes and found that adding postdiagnostic weight change as a factor improves the prediction.
By Leigh MacMillan
July 26, 2021

Mood and cognition after chemotherapy

Validation of cognitive complaints appears to improve mood in patients with persistent chemotherapy-cognitive impairment, Vanderbilt researchers report.
By Emily Stembridge
July 15, 2021

Susan G. Komen funds VICC breast cancer initiatives

Susan G. Komen has announced breast cancer research grants totaling $14 million, including funding for three separate initiatives led by Vanderbilt-Ingram Cancer Center (VICC) researchers.
By Tom Wilemon
July 1, 2021

Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma

A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.
By Tom Wilemon
1 … 16 17 18 19 20 … 65